PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.58%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-14.34%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-20.40%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-19.61%
Negative EPS growth while CRVO is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-20.61%
Negative diluted EPS growth while CRVO is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.76%
Share change of 0.76% while CRVO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.74%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-26.42%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-91846.40%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-21838.35%
Negative 5Y OCF/share CAGR while CRVO is at 98.43%. Joel Greenblatt would question the firm’s operational model or cost structure.
2.60%
3Y OCF/share CAGR under 50% of CRVO's 33.79%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-1109485.80%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20425.82%
Negative 5Y net income/share CAGR while CRVO is 16.45%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
78.21%
Positive short-term CAGR while CRVO is negative. John Neff would see a clear advantage in near-term profit trajectory.
41985.76%
Positive growth while CRVO is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
3459.24%
5Y equity/share CAGR above 1.5x CRVO's 92.41%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
143.15%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
Negative asset growth while CRVO invests at 107.86%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-29.04%
We have a declining book value while CRVO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
15.43%
We increase R&D while CRVO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
12.93%
SG&A declining or stable vs. CRVO's 51.78%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.